Education
About Us
Working with TipRanks
Follow Us
Sakar Healthcare Ltd (IN:SAKAR)
:SAKAR
SAKAR Stock Chart & Stats
₹406.55
-₹0.50(-0.17%)
At close: 4:00 PM EST
₹406.55
-₹0.50(-0.17%)
Day’s Range― - ―
52-Week Range₹210.10 - ₹569.95
Previous CloseN/A
Volume6.75K
Average Volume (3M)19.08K
Market Cap
₹11.31B
Enterprise Value₹12.03B
Total Cash (Recent Filing)₹2.16M
Total Debt (Recent Filing)₹718.62M
Price to Earnings (P/E)22.2
Beta0.61
Next Earnings
May 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.61
Shares Outstanding21,949,910
10 Day Avg. Volume18,950
30 Day Avg. Volume19,083
Financial Highlights & Ratios
PEG Ratio0.71
Price to Book (P/B)1.79
Price to Sales (P/S)2.88
P/FCF Ratio-37.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹605.00Price Target Upside48.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained mid-teens revenue growth demonstrates durable demand for the company's formulations and successful distribution/export reach. Over 2–6 months this supports scale benefits, stronger negotiating leverage with suppliers, and a bigger platform to fund R&D or contract manufacturing expansion.
Improving Operating Efficiency (EBIT)A materially higher EBIT margin indicates the company is extracting more operating leverage from sales growth and cost controls. Sustaining this margin expansion would enhance cash generation capacity and resilience to pricing pressure across its branded, generic and contract-manufacturing lines.
Stronger Capital StructureLower leverage and a high equity ratio provide financial flexibility for regulatory compliance, capacity investments and export growth. A healthier balance sheet reduces refinancing risk and supports longer-term strategic moves without relying heavily on external debt.
Bears Say
Sharp Gross Margin CompressionA severe fall in gross margin signals structural pressure on core product economics—higher input costs, pricing pressure, or product-mix shifts. If sustained, this erodes the company’s ability to fund SG&A and capex, making margin recovery and durable profitability uncertain.
Negative Free Cash FlowPersistently negative FCF, even if improving, limits internal funding for capex, working capital and strategic initiatives. Over months this increases reliance on external financing or equity, constraining agility for capacity additions or product launches and elevating liquidity risk.
Modest Return Metrics / ProfitabilityLow ROE and modest net margins indicate limited capital efficiency relative to peers. Over the medium term this can constrain reinvestment returns, reduce ability to build competitive differentiation, and pressure investor expectations if margins do not sustainably improve.
Sakar Healthcare Ltd News
SAKAR FAQ
What was Sakar Healthcare Ltd’s price range in the past 12 months?
Sakar Healthcare Ltd lowest stock price was ₹210.10 and its highest was ₹569.95 in the past 12 months.
What is Sakar Healthcare Ltd’s market cap?
Sakar Healthcare Ltd’s market cap is ₹11.31B.
When is Sakar Healthcare Ltd’s upcoming earnings report date?
Sakar Healthcare Ltd’s upcoming earnings report date is May 15, 2026 which is in 59 days.
How were Sakar Healthcare Ltd’s earnings last quarter?
Sakar Healthcare Ltd released its earnings results on Feb 05, 2026. The company reported ₹4.606 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.606.
Is Sakar Healthcare Ltd overvalued?
According to Wall Street analysts Sakar Healthcare Ltd’s price is currently Undervalued.
Does Sakar Healthcare Ltd pay dividends?
Sakar Healthcare Ltd does not currently pay dividends.
What is Sakar Healthcare Ltd’s EPS estimate?
Sakar Healthcare Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sakar Healthcare Ltd have?
Sakar Healthcare Ltd has 21,949,910 shares outstanding.
What happened to Sakar Healthcare Ltd’s price movement after its last earnings report?
Sakar Healthcare Ltd reported an EPS of ₹4.606 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 6.088%.
Which hedge fund is a major shareholder of Sakar Healthcare Ltd?
Currently, no hedge funds are holding shares in IN:SAKAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sakar Healthcare Ltd
Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable SVP in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in approximately 22 therapeutic areas, such as antacid, antimalerial, anticoagulant, laxative, anthelmintic, bronchodilator, anaesthetic, antidepressant, sedative, adrenergic, anti-infective, diuretics, oxytocic, analgesic, antiemetic, antipsychotic, antifungal, PPI, anticonvulsant, anti-inflammatory, antihistamine, and multi vitamins. The company also exports its products to approximately 38 countries, including Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India.
SAKAR Stock 12 Month Forecast
Average Price Target
₹605.00
▲(48.81% Upside)
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Kilitch Drugs (India) Limited
―
Medicamen Biotech Limited
―
Nectar Lifesciences Ltd.
―
Venus Remedies Limited
―